A Randomized, Double-blind Placebo-controlled Study of Treatments With Salmeterol, Fluticasone Propionate and Their Combination to Evaluate Novel Endpoints in Patients With Chronic Obstructive Pulmonary Disease
Latest Information Update: 06 Sep 2023
Price :
$35 *
At a glance
- Drugs Salmeterol (Primary) ; Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GSK
- 01 Apr 2009 New trial record